| Wnt/beta-Catenin Signalling and Its Cofactor BCL9L Have an Oncogenic Effect in Bladder Cancer Cells. | Wnt/β-Catenin Signalling and Its Cofactor BCL9L Have an Oncogenic Effect in Bladder Cancer Cells.
Kotolloshi R, Gajda M, Grimm MO, Steinbach D., Free PMC Article | 06/11/2022 |
| The interactions of Bcl9/Bcl9L with beta-catenin and Pygopus promote breast cancer growth, invasion, and metastasis. | The interactions of Bcl9/Bcl9L with β-catenin and Pygopus promote breast cancer growth, invasion, and metastasis.
Vafaizadeh V, Buechel D, Rubinstein N, Kalathur RKR, Bazzani L, Saxena M, Valenta T, Hausmann G, Cantù C, Basler K, Christofori G., Free PMC Article | 01/1/2022 |
| Type I collagen promotes tumor progression of integrin beta1 positive gastric cancer through a BCL9L/beta-catenin signaling pathway. | Type I collagen promotes tumor progression of integrin β1 positive gastric cancer through a BCL9L/β-catenin signaling pathway.
Lv Y, Shan Y, Song L, Zhao Y, Lai R, Su J, Zhang X., Free PMC Article | 12/11/2021 |
| BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer. | BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer.
Wang X, Feng M, Xiao T, Guo B, Liu D, Liu C, Pei J, Liu Q, Xiao Y, Rosin-Arbesfeld R, Shi Y, Zhou Y, Yang M, Feng YX, Jiang Y, Shao Z, Yu K, Zhu D. | 11/6/2021 |
| Dual-luciferase reporter confirmed that BCL9L is the target gene of both miR-22 and miR-214. | miR-22 and miR-214 targeting BCL9L inhibit proliferation, metastasis, and epithelial-mesenchymal transition by down-regulating Wnt signaling in colon cancer.
Sun R, Liu Z, Han L, Yang Y, Wu F, Jiang Q, Zhang H, Ma R, Miao J, He K, Wang X, Zhou D, Huang C. | 05/16/2020 |
| we identify BCL9L as a novel regulator of TGF-beta-induced EMT in pancreatic cancer. | Role of BCL9L in transforming growth factor-β (TGF-β)-induced epithelial-to-mesenchymal-transition (EMT) and metastasis of pancreatic cancer.
Sannino G, Armbruster N, Bodenhöfer M, Haerle U, Behrens D, Buchholz M, Rothbauer U, Sipos B, Schmees C., Free PMC Article | 03/10/2018 |
| BCL9L dysfunction contributes to aneuploidy tolerance in both TP53-WT and mutant cells by reducing basal caspase-2 levels and preventing cleavage of MDM2 and BID. | BCL9L Dysfunction Impairs Caspase-2 Expression Permitting Aneuploidy Tolerance in Colorectal Cancer.
López-García C, Sansregret L, Domingo E, McGranahan N, Hobor S, Birkbak NJ, Horswell S, Grönroos E, Favero F, Rowan AJ, Matthews N, Begum S, Phillimore B, Burrell R, Oukrif D, Spencer-Dene B, Kovac M, Stamp G, Stewart A, Danielsen H, Novelli M, Tomlinson I, Swanton C., Free PMC Article | 06/24/2017 |
| The inhibition of the transcriptional activity of BCL9-2 by WWOX and HDAC3 constitutes a new molecular mechanism and provides new insight for a broad range of cancers. | The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells.
El-Hage P, Petitalot A, Monsoro-Burq AH, Maczkowiak F, Driouch K, Formstecher E, Camonis J, Sabbah M, Bièche I, Lidereau R, Lallemand F. | 03/12/2016 |
| BCL9-2 induces ER positive breast cancers in vivo, regulates ER expression by a novel ss-catenin independent mechanism in breast cancer cells. | The BCL9-2 proto-oncogene governs estrogen receptor alpha expression in breast tumorigenesis.
Zatula N, Wiese M, Bunzendahl J, Birchmeier W, Perske C, Bleckmann A, Brembeck FH., Free PMC Article | 06/6/2015 |
| Data show that beta-catenin/BCL9-Like (BCL9L)/T-cell factor 4 (TCF4) signalling directly targets the GCM1/syncytin pathway and thereby regulates the fusion of human choriocarcinoma cells. | Identification of a link between Wnt/β-catenin signalling and the cell fusion pathway.
Matsuura K, Jigami T, Taniue K, Morishita Y, Adachi S, Senda T, Nonaka A, Aburatani H, Nakamura T, Akiyama T. | 05/19/2012 |
| BCL9-2 promotes early phases of intestinal tumor progression in humans and in transgenic mice. BCL9-2 increases the expression of a subset of canonical Wnt target genes but also regulates genes that are required for early stages of tumor progression. | BCL9-2 promotes early stages of intestinal tumor progression.
Brembeck FH, Wiese M, Zatula N, Grigoryan T, Dai Y, Fritzmann J, Birchmeier W. | 12/3/2011 |
| Pygo2 PHD is the only known PHD finger that is capable of interacting simultaneously with two functional ligands, B9L and BCL9. | Allosteric remodelling of the histone H3 binding pocket in the Pygo2 PHD finger triggered by its binding to the B9L/BCL9 co-factor.
Miller TC, Rutherford TJ, Johnson CM, Fiedler M, Bienz M., Free PMC Article | 10/29/2010 |
| crystallographic analysis of how beta-catenin, BCL9, BCL9-2 and Tcf4 interact | Crystal structure of a beta-catenin/BCL9/Tcf4 complex.
Sampietro J, Dahlberg CL, Cho US, Hinds TR, Kimelman D, Xu W. | 01/21/2010 |